双歧杆菌三联活菌肠溶胶囊治疗婴儿支气管肺炎并症状性腹泻疗效观察

目的观察双歧杆菌三联活菌肠溶胶囊（贝飞达）治疗婴儿支气管肺炎并症状性腹泻的疗效。方法156例婴儿支气管肺炎并症状性腹泻患儿随机分为2组,对照组72例按支气管肺炎常规抗感染及对症治疗,治疗组84例在此基础上加用双歧杆菌三联活菌。结果治疗组有效率为82．2％,显著高于对照组（58．3％）,2组间差异有非常显著性（χ^2=10．7,P〈0．01）。结论双歧杆菌三联活菌治疗婴儿支气管肺炎并症状性腹泻疗效显著。     

贝飞达治疗小儿迁延性腹泻的临床研究

目的评价贝飞达治疗小儿迁延性腹泻的临床疗效,为合理应用贝飞达治疗小儿迁延性腹泻提供科学依据。方法选取60例1个月～2岁的迁延性腹泻患儿为研究对象,把他们随机分为贝飞达组和常规组。另30例1个月-2岁的健康儿作为对照组;3组均进行治疗前后粪便中的4种常驻的正常菌群的测定和60例迁廷性腹泻患儿疗效、住院时间及费用的观察。结果贝飞达组总有效率明显高于常规组,且住院时间及费用也明显减少。治疗前60例迁延性腹泻患儿的粪便菌群中双歧杆菌、乳杆菌明显减少,肠球菌、肠杆菌增加,与健康同龄儿比t〈0．05,治疗后贝飞达组粪便菌群中的4种菌群数比常规组增加明显结论贝飞达具有调整肠道菌群失调的作用,从而提高疗效。     

贝飞达治疗肠易激综合征289例临床观察

目的：探讨微生态制剂贝飞达对肠易激综合征的疗效。方法：采用中国预防医学科学院流研所海斯药业有限公司生产的双歧三联活菌胶囊贝飞达治疗怕易激综合征患者289例,分别观察临床症状改善情况,结果：此药对腹痛,腹泻,腹胀和便秘的有效率均在80%以上,结论：贝飞达可迅速,有效地缓减肠易激综合征的症状,无毒副作用,值得推广,是治疗肠易激综合征的一个有效新型微生态制剂。     

金双歧治疗肠易激综合征患者疗效观察

目的 探讨金双歧活菌制剂治疗肠易激综合征（IBS）患者的临床疗效和对菌群失调的调整作用。方法 64例患者随机分成2组.治疗组35例,口服金双歧活菌制剂（每粒含活菌0.5亿）,4片/次,2次/d,连服1个月;对照组29例,口服安慰剂胶囊,疗程同治疗组.评价标准系采用积分法。结果 治疗组治疗效果与对照组相比差异有显著性（P＜0.05）。患者治疗后肠道中双歧杆菌、类杆菌和肠杆菌数量明显上升。结论 金双歧活菌制剂能纠正肠道菌群失调,对IBS患者有良好的治疗作用。     

肠疗与贝飞达合用治疗急性黄疸型肝炎的研究

目的 对90例急性黄疸型肝炎患者分别测定应用肠疗和贝飞达治疗前、后肠道菌群数量和红细胞粘附率、红细胞CR1分子数量及临床疗效评价指标,并进行比较。方法 将患者随机分成常规治疗、常规治疗加肠疗、常规治疗加肠疗与贝飞达3个治疗组（各30例）。分析患者治疗前后血液生化指标和肠道菌群数量及红细胞粘附率、红细胞CR1分子数量,并观察临床症状的改善情况。结果 急性黄疸型肝炎患者存在肠道菌群失调,红细胞粘附肿瘤功能及红细胞CR1分子数量明显下降（P〈0．01）;应用微生态调节剂组患者的肝功能恢复程度及临床症状的改善好于常规治疗组和常规治疗加肠疗组,差异有显著性（P〈0．01）。结论 结肠治疗机治疗联合微生态调节剂贝飞达可以有效改善急性黄疸型肝炎患者肠道菌群失调,提高患者红细胞粘附率及红细胞CR1分子数量,提高临床治疗有效率。     

金双歧联合丁螺环酮治疗肠易激综合征的临床疗效观察

目的 观察并分析金双歧联合丁螺环酮治疗肠易激综合征的临床疗效.方法 对80例门诊患者,年龄在18～70岁,采用随机数字表法,分为治疗组40例,采用金双歧联合丁螺环酮治疗;对照组40例,采用单用金双歧治疗,两组其他内科常规治疗相同,疗程4周,评估两组治疗前后临床疗效及汉密尔登焦虑(HAMA)和汉密尔登抑郁(HAMD)量表评分变化.结果 治疗前,两组IBS症状、肠外症状、生活质量、汉密尔登焦虑和抑郁量表评分比较差异无统计学意义.治疗后两组IBS症状、肠外症状、生活质量治疗后均较治疗前明显改善,联合治疗组较单用金双歧组更显著.汉密尔登焦虑和抑郁量表评分两药联合治疗后显著改善,但单用金双歧无明显改善.结论 金双歧联合丁螺环酮治疗肠易激综合征,安全、有效、不良反应少.     

微生态制剂(双歧三联活菌胶囊)治疗肠易激综合征的临床观察

双歧三联活菌胶囊(贝飞达,Bifido)是中国预防医学科学院流研所海斯药业有限公司开发出的新一代微生态制剂,为长双歧杆菌、嗜酸乳杆菌、粪肠球菌经适当配合制成的活菌制剂,该3种菌皆分离自健康人体,易于在肠道定植,能直接补充肠道正常生理细菌,通过生物拮抗,抑制病原菌,调整肠道菌群失调,改善肠道功能和肝功能,增强免疫,预防肠道肿瘤等多种生理作用.我科用双歧三联活菌胶囊治疗腹泻型肠易激综合征(irritable bowel syndrome,IBS),旨在评价双歧在联活菌胶囊在IBS治疗中的疗效和安全性,探讨肠道感染和肠道菌群失调与IBS的发病关系.     

双歧三联活菌胶囊对腹泻型肠易激综合征患者肠道菌群的影响及疗效观察

目的探讨双歧三联活菌胶囊对腹泻型肠易激综合征（IBS—D）患者肠道菌群的影响及疗效观察。方法将IBS—D患者70例随机分为观察组和对照组。两组患者均予以凋整饮食、胃肠解痉药和止泻药等常规治疗。观察组患者予以口服双歧杆菌三联活菌胶囊420mg,3次／d．温开水送服,连用4周。观察两组患者治疗前后肠道菌群的变化,并比较其临床疗效。结果治疗4周后,观察组患者双歧杆菌、乳酸杆菌数量较前增加,肠杆菌、肠球菌、酵母菌数量较前减少（P〈0．05）,但对照组治疗前后无明显变化（P〉0．05）;同时观察组患者临床总有效率（94．29％）明显优于对照组（74．29％）（χ2=5．29,P〈0．05）。结论双歧二三联活菌胶囊治疗IBS—D疗效较好,作用于其能调节患者肠道菌群紊乱,重建肠道微生态平衡密切相关。     

金双歧治疗肠易激综合征142例的疗效观察

目的：观察金双歧（长双歧杆菌制剂）对肠易激综合征（irritablebowel syndrome,IBS)的治疗效果。方法：顺序随机取本院门诊按“罗马标准I”的诊断标准确诊为IBS患者142例入组,接受金双歧治疗,所有病人均排除器质性疾病。IBS患者口服双歧2.,0g,2次／d为一疗程。观察期间记录前及治疗后每一天的包括腹痛,腹胀,排便频率,排便异常和大便性状的病状积分和不良反应。结果：治疗1－2周后的总体征候和单项症状积分均有明显改善,总体征候显效率分别达24.6%-40.8%,总有效率分别达65.4%-85.2%,无一例发生不良反应。结论：长双歧杆菌制剂治疗IBS疗效确切,病人依从好,值得推广应用。     

双歧杆菌三联活菌肠溶胶囊对高脂饮食所致大鼠非酒精性脂肪肝的疗效及机制探讨

目的 观察微生态制剂贝飞达(双歧杆菌三联活菌肠溶胶囊)治疗高脂饮食所致大鼠非酒精性脂肪肝的疗效并探讨其可能的作用机制.方法 雄性SD大鼠32只,适应性饲养1周后,随机分为3组,正常组:12只给予普通饲料喂养;模型组:12只,贝飞达治疗组:8只,均给予高脂饲料喂养;于喂养12周末正常组及模型组各处死4只,经肝组织HE染色确定造模成功后,贝飞达治疗组给予贝飞达[0.113 g/(kg·d)]灌胃,于16周末全部处死.检测大鼠血清AST、ALT、TC、TG、LDL、HDL、血清内毒素水平,观察其肝组织学变化.结果 模型组于高脂饲料喂养12周末出现脂肪肝,与正常组比较,模型组大鼠血清AST、ALT、TG、TC、LDL、HDL及血清内毒素水平均明显升高(P＜0.01).贝飞达治疗组大鼠各项指标较模型组均有显著改善,肝脏脂肪变性程度减轻.结论 微生态制剂贝飞达可能通过改善肠道菌群紊乱,减轻内毒素血症,从而调节肝脏脂质代谢紊乱,对非酒精性单纯性脂肪肝起到治疗作用.     

回春生胶囊治疗肠易激综合征菌群失调的研究

本文报道应用回春生胶囊（丽珠肠乐）治疗肠易激综合征（ＩＢＳ）和对菌群失调疗效研究结果。６４例病人,随机分成两组,治疗组３５例,回春生胶囊每次１亿活菌,一日２次,连续服用１个月：回春生胶囊治疗后的积分为治疗前的４０．７％（３７／９１）,较对照组有显著差异（Ｐ＜０．０５）。另外,全部病人还进行了粪便的９种常见厌氧菌和需氧菌的定量研究。结果发现治疗后双歧杆菌、类杆菌和肠杆菌的数值呈明显增加,说明回春生胶囊是通过补充双歧杆菌的数量,纠正肠菌群失调,对ＩＲＳ有良好的治疗作用。     

丽珠肠乐治疗溃疡性结肠炎的临床疗效及病理变化的研究

目的:探讨溃疡性结肠炎的微生态学改变及双歧杆菌对溃疡性结肠炎的预防和治疗作用.方法:随机选取溃疡性结肠炎的患者60人,分成二组.治疗组:口服丽珠肠乐胶囊;对照组:口服氟哌酸胶囊,柳氮磺胺吡啶栓直肠给药.疗程一个月.结果:溃疡性结肠炎的肠道内细菌数量双歧杆菌、乳杆菌显著下降(P＜0.01),肠球菌显著增加(P＜0.01).经丽珠肠乐治疗后,肠道内主要细菌的数量恢复正常,与对照组相比差异有显著性(P＜0.01);肠道黏膜病理及组织学改变基本恢复正常;临床症状改善上治疗组疗效高于对照组(P＜0.01).结论:双歧杆菌活菌制剂治疗溃疡性结肠炎效果显著,值得临床推广使用.     

西甲硅油联合枯草杆菌肠球菌对肠易激综合征的疗效观察

目的:探讨西甲硅油乳剂联合枯草杆菌肠球菌二联活菌肠溶胶囊(美常安)在肠易激综合征(IBS)治疗中的临床效果。方法:将2014年1月至2015年10月收治的180例IBS患者随机分为西甲硅油乳剂联合枯草杆菌肠球菌二联活菌治疗组92例和单药枯草杆菌肠球菌二联活菌治疗对照组88例,治疗4周后随访观察两组患者的治疗总有效率、不同胃肠症状的治疗有效率,以及不同型IBS患者的胃肠症状评分。结果:IBS治疗组的治疗总有效率为88.0%,明显高于对照组70.5%(P0.05)。治疗4周后腹胀和排便次数改善的有效率分别为94.6%和78.3%明显高于对照组的77.3%和60.2%(P0.05),但两组在腹痛和排便性状改善方面比较无明显差异(P0.05)。对两组不同胃肠症状评分结果:显示同组同型IBS治疗4周后胃肠症状评分均明显低于治疗前(P0.05)治疗有效。但两组同型IBS患者的治疗后胃肠症状评分比较时,仅在便秘型IBS患者差异明显(P0.05)。结论:西甲硅油乳剂联合枯草杆菌二联活菌肠溶胶囊对肠易激综合征(IBS)患者治疗有效,对缓解腹胀和改善排便次数上治疗效果尤为明显,对IBS便秘型患者的胃肠症状恢复疗效最佳。     

Evaluation of in vitro antagonism and of in vivo immune modulation and protection against pathogenic experimental challenge of two probiotic strains of Bifidobacterium animalis var. lactis

The aim of the present study was to compare the effect of intragastric administration with two strains of Bifidobacterium animalis subsp. lactis (Bifido A and Bifido B), in gnotobiotic and conventional mice, challenged with Salmonella Typhimurium. In vitro antagonism test showed that the two strains were able to produce antagonistic substances against various pathogenic microorganisms. In an ex vivo antagonism test the production of antagonistic substances was observed only against three out ten pathogens tested. Both Bifidobacterium strains were able to colonize and to maintain high population levels in the digestive tract of gnotobiotic mice. In addition, the two strains had low and limited translocation ability and did not cause any histological lesion in any of the organs analyzed. Both strains were able to reduce the fecal number of Salmonella in gnotobiotic mice challenged with the pathogen, but only Bifido B was able to confer a protection as demonstrated by a lower mortality. Higher levels of sIgA and IL-10 were observed only in Bifido B mono-associated mice when compared to germ free group. We could conclude that, among the parameters analyzed, the strain Bifido B exhibited the more desirable characteristics to be used as a probiotic.     

美常安干预肠易激综合征伴小肠细菌过度生长的研究

目的通过美常安干预肠易激综合征(IBS)伴小肠细菌过度生长(SIBO)患者,探讨IBS与SIBO之间的关系。方法选取40例IBS患者为IBS组,40例健康志愿者为对照组,两组患者治疗前均进行乳果糖氢呼气试验(LHBT)明确SIBO情况。IBS组中SIBO阳性者予美常安干预,观察其治疗前后的症状变化,疗程结束后复查LHBT。结果 IBS组患者SIBO发病率为55.0%,对照组为10.0%,两组患者SIBO发病率比较差异有统计学意义(P0.05);IBS组中SIBO阳性患者治疗后显效1例,有效12例,无效6例,脱落3例,有效率为68.0%,SIBO转阴率为57.9%。IBS组中SIBO阳性患者治疗前后腹胀程度、排便频率异常时间、排便时腹痛率及总积分比较差异有统计学意义(P0.05)。结论 IBS患者SIBO发病率远高于健康者,美常安能改善IBS伴SIBO患者部分症状及SIBO发病率,IBS的发生与SIBO之间存在一定关系,但对于IBS患者单纯补充益生菌制剂疗效并不理想,仍需结合其他手段进行干预。     

酪酸梭菌活菌片联合 马来酸曲美布汀、谷维素对IBS患者的疗效

目的探讨酪酸梭菌活菌片联合马来酸曲美布汀、谷维素对肠易激综合征患者的临床疗效。方法选择80例肠易激综合征患者,随机分为治疗组(n=40)和对照组(n=40)。治疗组患者采用酪酸梭菌活菌片联合马来酸曲美布汀、谷维素进行治疗,对照组患者采用马来酸曲美布汀和谷维素进行治疗。结果治疗组患者有效率高于对照组,两组疗效比较差异有统计学意义(P0.05)。结论酪酸梭菌活菌片联合马来酸曲美布汀、谷维素对肠易激综合征患者疗效显著。     

Relationship between cognitive appraisals of symptoms and negative mood for subtypes of irritable bowel syndrome

Background

The onset and course of irritable bowel syndrome (IBS) are strongly influenced by psychological factors, and treatment often includes cognitive-behavioral therapy. We conducted a study of the relationships between cognitive appraisal of IBS symptoms and negative mood for the subtypes of IBS.

Method

The participants were 1087 college students who completed a set of questionnaires that included the Rome II Modular Questionnaire, Self-reported IBS Questionnaire, Cognitive Appraisal Rating Scale, and the Hospital Anxiety and Depression Scale.

Results

The participants included 206 individuals with IBS; 61 had diarrhea-predominant IBS (IBSD) and 45 had constipation-predominant IBS (IBSC). The overall IBS group scored higher on anxiety and depression than the control group. The IBSD and IBSC groups each had significantly higher scores for anxiety but did not significantly differ from the control group in scores for depression. There were no significant differences between the IBSD and IBSC groups in their cognitive appraisal of IBS symptoms. For the IBSD group, anxiety was significantly, positively correlated with commitment, effect, and threat, and depression was significantly, negatively correlated with controllability. In contrast, there were no significant correlations between mood and cognitive appraisal for the IBSC group. Multiple regression analyses with abdominal symptoms as dependent variables and cognitive appraisals as independent variables showed that for the IBSD group, abdominal pain was significantly, positively correlated with commitment, and abdominal discomfort was significantly, positively correlated with appraisal of effect and threat. For the IBSC group, abdominal pain and hard stool were significantly, positively correlated with commitment, and abdominal discomfort was significantly, positively correlated with appraisal of effect and threat.

Conclusion

IBS patients as a general group report high levels of anxiety and depression. However, IBSD and IBSC were both associated only with high anxiety, but not depression, when compared to the non-IBS control group. For the IBSD group, anxiety was associated with cognitive appraisals, but this association was not found for the IBSC group. These groups did not differ in their associated cognitive appraisals, and are similar in terms of the positive relationship between abdominal pain and discomfort and the cognitive appraisals of coping.

     

Gut Microbiota is Not Modified by Randomized, Double-Blind, Placebo-Controlled Trial of VSL#3 in Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome (IBS) is a common condition that negatively impacts the quality of life for many individuals. The exact etiology of this disorder is largely unknown; however, emerging studies suggest that the gut microbiota is a contributing factor. Several clinical trials show that probiotics, such as VSL#3, can have a favorable effect on IBS. This double-blind, randomized placebo-controlled study has been conducted in diarrhea-predominant IBS subjects in order to investigate the effect of VSL#3 on the fecal microbiota. The bacterial composition of the fecal microbiota was investigated using high-throughput microarray technology to detect 16S RNA. Twenty four subjects were randomized to receive VSL#3 or placebo for 8 weeks. IBS symptoms were monitored using GSRS and quality of life questionnaires. A favorable change in Satiety subscale was noted in the VSL #3 groups. However, the consumption of the probiotic did not change the gut microbiota. There were no adverse events or any safety concerns encountered during this study. To summarize, the use of VSL#3 in this pilot study was safe and showed improvement in specific GSRS-IBS scores in diarrhea-predominant IBS subjects. The gut microbiota was not affected by VSL#3 consumption suggesting that the mechanism of action is not directly linked to the microbiota.